{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-008492","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2022-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.351262+00:00","generated_at":"2026-06-25T22:34:42.489293+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"ORIC Pharma Q1 2022: $256.2M cash runways into 2H2024; three Phase 1b data readouts in 1H2023","bullets":["Cash and investments $256.2M as of March 31, 2022; expected to fund operations into 2H2024.","R&D expenses $16.8M (up $5.1M YoY) driven by advancing ORIC-533, -114, -944; ORIC-101 discontinued.","G&A expenses $6.4M (up $1.6M YoY) due to higher personnel costs.","Three Phase 1b trials (ORIC-533 in multiple myeloma; ORIC-114 in EGFR/HER2; ORIC-944 in prostate) targeting initial data in 1H2023.","PLK4 inhibitor program in lead optimization for TRIM37-amplified breast cancers."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-008492","json":"https://secwatch.observer/filing/0000950170-22-008492.json","markdown":"https://secwatch.observer/filing/0000950170-22-008492.md","text":"https://secwatch.observer/filing/0000950170-22-008492.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000095017022008492/0000950170-22-008492-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000095017022008492/oric-20220509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T22:34:42.489293+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}